Covance, Inc. (CVD)
A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.
Recs
Strong Sector for 2010
Recs
Recs
Showed up on a screen for solid 5 year growth with low debt, cash on hand and still at attractive P/E ratios.
Recs
drus will go up
Recs
Blanket pick on the CRO market under the assumption that it will return to growth in 2010. This just seems like the right time to make this call (we'll see).
TMFHelical
Recs
best name in CRO industry; services valued highly by their clients.
Recs
I have bull picks on all of these companies ICON, PRXL etc.
Recs
Pharma outsourcing will benefit CROs in the long run.
Recs
Low Relative PE, good caps score, upcoming earnings not too bad decent lt growth prospects - bottom fishing.
Recs
Recs
CVD is the tool that most drug companies need to employ to replenish their stable of proprietary drugs. They do not need to sell drugs, but need the demand to bring new drugs to market.
Recs
contract research organization (CRO) should benefit of increasing drug tests and testing to get FDA approval.
Recs
Pummeled. Absolutely pummeled. From $100 to $40 this year.
But the company remains solid in every respect, and is almost guaranteed a comeback. Not to mention that the biotech sector is seeing some action as a hedge against a recession. I'm loading up on biotechs, but would probably take CVD either way.
I put it at $60 by June.
Recs
Pharma is among the least affected industries, however they are seeking cost reductions, effiiciency gains, etc like everyone else. The usual and likely avenue for that is CROs, and if you read the news for this company, they are already reeping rewards.
Recs
Will benefit from pharma outsourcing
Recs
FIrstly it's quite clear this one has only dropped because of the market volatility. A sector leader constantly improving on itself, as is evidenced in a number of accolades this year from its own customers. The only thumbs down below is obviously from a peta activist -- all sane writers here are thumbs up. Other than a full blown market crash, this one practically HAS to go back up. 60$ easy when the indices trend up, 80$ when recession talk dies, and 100$ a year after that.
Recs
Recs
Worldwide drug development needed - great entry point & 71-0 outperform calls by caps all stars
Recs
Victim of maket hysteria. An absolute bargain in the 40s.
Recs
Rise of CROs and the Downsizi g and Globilization of Big Pharma R&D.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 45 1 2 3 Next »